Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 19 March

Sam Kanaan
March 19, 2024

Morning Bell 18 March

Sophia Mavridis
March 18, 2024

Weekly Wrap 15 March

Grady Wulff
March 15, 2024

Morning Bell 15 March

Sam Kanaan
March 15, 2024

Morning Bell 14 March

Sophia Mavridis
March 14, 2024

Morning Bell 13 March

Sam Kanaan
March 13, 2024

Morning Bell 12 March

Sam Kanaan
March 12, 2024

Morning Bell 11 March

Sam Kanaan
March 11, 2024

Weekly Wrap 8 March

Sophia Mavridis
March 8, 2024

Morning Bell 8 March

Sam Kanaan
March 8, 2024

Morning Bell 7 March

Sophia Mavridis
March 7, 2024

Morning Bell 6 March

Sam Kanaan
March 6, 2024